CBIO vs AURA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

CBIO

31.4
AI Score
VS
AURA Wins

AURA

45.1
AI Score

Investment Advisor Scores

CBIO

31score
Recommendation
SELL

AURA

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CBIO AURA Winner
Net Income 153,942 -79.32M CBIO
Operating Income -152.63M -82.94M AURA
ROE 0.1% -25.2% CBIO
ROA 0.1% -22.8% CBIO
Total Assets 240.29M 348.13M AURA
Cash 213.19M 67.84M CBIO
Current Ratio 6.56 16.82 AURA
Free Cash Flow -72.45M -62.52M AURA

Relative Price Performance (Last 90 Days)

CBIO 1M: +18.1% · 3M: +5.8% AURA 1M: -9.7% · 3M: +12.6%

Current Technical Phase

CBIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.8% over 20 days), RSI 58

RSI (14): 58.0 · Price: $19.41

AURA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 40

RSI (14): 39.8 · Price: $7.00

Fundamentals Snapshot

Metric CBIO AURA
Market Cap
Forward P/E -7.4 -4.6
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 1.0%
Operating Margin -14.3% 0.0%
EPS -0.14 -1.68
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, AURA is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.